

# HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program



<b>Performance Measure: ADAP: Application Determination</b>	
Percent of ADAP applications <sup>1</sup> approved or denied for new ADAP enrollment <sup>2</sup> within 14 days (two weeks) of ADAP receiving a complete application in the measurement year	
<b>Numerator:</b>	Number of applications that were approved or denied for new ADAP enrollment <sup>1</sup> within 14 days (two weeks) of ADAP receiving a complete application in the measurement year
<b>Denominator:</b>	Total number of complete ADAP applications for new ADAP enrollment <sup>2</sup> received in the measurement year
<b>Exclusions:</b>	<ol style="list-style-type: none"> <li>1. ADAP applications for new ADAP enrollment<sup>2</sup> that were incomplete or incorrectly filled out.</li> <li>2. Complete ADAP applications for new ADAP enrollment<sup>2</sup> received by ADAP within the last 14 days (two weeks) of the measurement year.</li> </ol>
<b>Data Element:</b>	<ol style="list-style-type: none"> <li>1. Did the client apply for new ADAP enrollment<sup>2</sup> during the measurement year? (Y/N)               <ol style="list-style-type: none"> <li>a. If yes, was a determination on the application made by the ADAP program? (Y/N)                   <ol style="list-style-type: none"> <li>i. If yes, list the date of receipt of the complete application and date of approval or denial.</li> </ol> </li> </ol> </li> </ol>
<b>Data Sources:</b>	<ul style="list-style-type: none"> <li>• AIDS Drug Assistance Program Quarterly Data Report</li> </ul>
<b>National Goals, Targets, or Benchmarks for Comparison:</b>	Part B Collaborative <sup>3</sup> : 97% Part B Low Incidence Initiative <sup>4</sup> : 100%
<b>Basis for Selection:</b>	
Timely review for ADAP eligibility can ensure timely access to medications. This quality measure has been used by the Part B Collaborative and Low Incidence Initiative to measure performance and to develop successful improvement projects to decrease the length of time to determine ADAP eligibility or ineligibility by the ADAP program.	
<b>US Public Health Service Guidelines:</b>	
This measure addresses the intent of HHS Treatment Guidelines for the use of antiretroviral agents and the prevention and treatment of opportunistic infections in HIV-infected individuals. <sup>5-9</sup>	
<b>References/Notes:</b>	
<sup>1</sup> Includes applications for all individuals, regardless of age.  <sup>2</sup> New ADAP enrollment “refers to individuals who applied to ADAP for the first time ever... [This does not] include individuals who have been recertified as eligible or individuals who have been reinstated as enrolled clients after a	

# HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program

## Performance Measure: ADAP: Application Determination

period of having been decertified. Examples of clients who should **not** be included [as a new ADAP enrollment] are the following: 1) clients who have moved out of the State and then returned; and 2) clients who move on and off ADAP because of fluctuations in eligibility for a Medicaid/Medically Needy program, based on whether they met spend down requirements.”

[Source: “Instructions for Completing The Drug Assistance Program Quarterly Data Report”. Available at [http://ftp.hrsa.gov/hab/ADAP%20Instructions\\_Final%20Feb%202022\\_08\\_.pdf](http://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20Feb%202022_08_.pdf). Accessed July 17, 2009.]

<sup>3</sup> Part B Collaborative measure reads: “Percent of ADAP applicants approved or denied for ADAP enrollment within two weeks of ADAP receiving a complete application”.

<sup>4</sup> Part B Low Incidence Initiative measure reads: “Percent of applying state ADAP clients approved/denied for ADAP services within two weeks of ADAP receiving a complete application”.

<sup>5</sup> Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161.. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed December 7, 2009.

<sup>6</sup> Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009; pp 47. Available at <http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf>. Accessed September 9, 2009.

<sup>7</sup> Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009; pp 1-90. Available at <http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf>. Accessed September 9, 2009.

<sup>8</sup> Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009;58(No. RR-4): 1-216. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf>. Accessed September 9, 2009.

<sup>9</sup> Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58(No. RR-11): 1-176. Available at: [http://aidsinfo.nih.gov/contentfiles/Pediatric\\_OI.pdf](http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf). Accessed September 9, 2009.